Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.34 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 3/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5949013 | 0.93 | ESR1 (0.38) | TSHRPLA2G1BPLA2G2AESR1ESR2 | |
| SCHEMBL5948888 | 0.90 | TSHR (0.36) | TSHRALDH1A1PLA2G1BPLA2G2AESR1 | |
| SCHEMBL915195 | 0.88 | KCNH2 (0.37) | PLA2G1BPLA2G2ACA12CA1CA9 | |
| SCHEMBL5948823 | 0.84 | MEN1 (0.33) | TSHRALDH1A1MEN1POLBKMT2A | |
| SCHEMBL23451757 | 0.81 | SIGMAR1 (0.35) | ALDH1A1MEN1POLBKMT2AKCNH2 | |
| SCHEMBL17389361 | 0.81 | TSHR (0.41) | TSHRPLA2G1BPLA2G2AESR1ESR2 | |
| SCHEMBL11798925 | 0.81 | ALDH1A1 (0.38) | TSHRALDH1A1 | |
| SCHEMBL5949182 | 0.80 | ALDH1A1 (0.32) | ALDH1A1PLA2G1BPLA2G2AMEN1POLB | |
| SCHEMBL23451565 | 0.79 | SIGMAR1 (0.34) | ALDH1A1MEN1POLBKMT2AKCNH2 | |
| SCHEMBL23451783 | 0.79 | SIGMAR1 (0.34) | ALDH1A1MEN1POLBKMT2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101940-B2 | Chemical compound, method for the production thereof and its use in catalyst systems for producing polyolefins | BASELL POLYOLEFINE GMBH (DE) | 2006-09-05 | — | — | US | disclosed |
| US-7034173-B2 | Chemical products suited for use as co-catalysts, method for the preparation thereof and their use in catalyst systems for producing polyolefins | BASELL POLYOLEFINE GMBH (DE) | 2006-04-25 | — | — | US | disclosed |
| US-6953829-B2 | Catalyst system and the use thereof | BASELL POLYOLEFINE GMBH (DE) | 2005-10-11 | — | — | US | disclosed |
| US-20030144434-A1 | Chemical products suited for use as co-catalysts, method for the preparation thereof and their use in catalyst systems for producing polyolefins | EQUISTAR CHEMICALS, LP | 2003-07-31 | — | — | US | disclosed |
| US-20030013913-A1 | Chemical compound, method for the production thereof and its use in catalyst systems for producing polyolefins | EQUISTAR CHEMICALS, LP | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144434-A1 | Chemical products suited for use as co-catalysts, method for the preparation thereof and their use in catalyst systems for producing polyolefins | CBR1, COX6C, CBR3 | TSHR 2182/4885ALDH1A1 274/4885PLA2G1B 1146/4885 |
| US-20030013913-A1 | Chemical compound, method for the production thereof and its use in catalyst systems for producing polyolefins | SCO2, CNOT1, CYC1 | TSHR 3975/4885ALDH1A1 1134/4885PLA2G1B 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.